<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000833</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 274</org_study_id>
    <secondary_id>11250</secondary_id>
    <nct_id>NCT00000833</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.</brief_title>
  <official_title>A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To compare the safety, toxicity, and tolerance of two doses of ribavirin in combination with&#xD;
      didanosine (ddI) to HIV-infected children. To determine the toxicity of ddI/ribavirin and&#xD;
      compare it to the expected toxicity of ddI monotherapy. To determine the effect of concurrent&#xD;
      ribavirin on the pharmacokinetics of ddI. To determine a dosage of ribavirin that would be&#xD;
      suitable for a Phase II/III evaluation of ddI/ribavirin.&#xD;
&#xD;
      Ribavirin, a broad spectrum antiviral agent, may enhance the antiretroviral activity of&#xD;
      didanosine ( ddI ) without a concomitant increase in toxicity. Ribavirin alters the&#xD;
      intracellular metabolism of ddI, enhancing the antiretroviral activity of the active form of&#xD;
      ddI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ribavirin, a broad spectrum antiviral agent, may enhance the antiretroviral activity of&#xD;
      didanosine ( ddI ) without a concomitant increase in toxicity. Ribavirin alters the&#xD;
      intracellular metabolism of ddI, enhancing the antiretroviral activity of the active form of&#xD;
      ddI.&#xD;
&#xD;
      Patients are divided into two cohorts. Subjects will be stratified by age 3 months to &lt; 24&#xD;
      months and &gt;= 24 months to 12 years. Fifty % of patients from each age group will be assigned&#xD;
      to each cohort. Cohort 1 receives ddI monotherapy for 4 weeks, followed by combination&#xD;
      ddl/ribavirin therapy for an additional 20 weeks. Cohort 2 receives combination ddI/ribavirin&#xD;
      for 24 weeks. In both cohorts, after study medications are stopped, patients are treated with&#xD;
      prescription antiretrovirals for 4 more weeks. [AS PER AMENDMENT 7/2/96: Note: In each cohort&#xD;
      of 10 subjects at least 2 of 5 children from the older half of the cohort will have an ICD&#xD;
      p24 antigen at entry.]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">July 1998</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Recommended:&#xD;
&#xD;
          -  PCP prophylaxis.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Acetaminophen for no more than 72 hours.&#xD;
&#xD;
          -  Immunoglobulin.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Erythropoietin.&#xD;
&#xD;
          -  G-CSF and GM-CSF.&#xD;
&#xD;
          -  Ethionamide or isoniazid for TB if no alternative available.&#xD;
&#xD;
          -  Immunizations according to current recommendations.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Immunologic abnormality or clinical symptoms as detailed in the Disease Status field.&#xD;
&#xD;
          -  No active AIDS-defining opportunistic infection or malignancy, no progressive&#xD;
             encephalopathy attributable to HIV and no chronic persistent diarrhea.&#xD;
&#xD;
          -  Consent of parent or guardian.&#xD;
&#xD;
        PER AMENDMENT 7/2/96:&#xD;
&#xD;
          -  At least 2 of the 5 children in the older half of each cohort must have an ICD p24&#xD;
             antigen concentration &gt;= 70 pg/ml at screening.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Up to 6 weeks of prior immunomodulator therapy.&#xD;
&#xD;
          -  Maternal immunomodulator or antiretroviral therapy, including during pregnancy.&#xD;
&#xD;
          -  Prior corticosteroids or intravenous immunoglobulin.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Current grade 3 or worse neuropathy/lower motor neuropathy.&#xD;
&#xD;
          -  Clinical or laboratory grade 3 or worse toxicities.&#xD;
&#xD;
          -  Active serious bacterial infection.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Chemotherapy for active malignancy.&#xD;
&#xD;
          -  Antiretrovirals other than study drugs.&#xD;
&#xD;
          -  Immunomodulators unless specifically allowed.&#xD;
&#xD;
        Patients with the following prior condition are excluded:&#xD;
&#xD;
          -  History of grade 3 or worse neuropathy/lower motor neuropathy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior ddI or oral ribavirin.&#xD;
&#xD;
          -  Aerosolized ribavirin within 6 weeks prior to study entry.&#xD;
&#xD;
          -  Antiretroviral or immunomodulator therapy (other than corticosteroids or IVIG) within&#xD;
             1 week prior to blood draws for study entry.&#xD;
&#xD;
        Ongoing drug or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Van Dyke R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>McSherry G</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hosp of Washington DC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>200102916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ Hosp</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Florida Health Science Ctr / Pediatrics</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ / Charity Hosp of New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>701122699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>021155724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Medicine &amp; Dentistry of New Jersey / Univ Hosp</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>071032714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>071072198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Lebanon Hosp Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Hosp</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Incarnation Children's Ctr / Columbia Presbyterian Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaxo Wellcome Inc</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <zip>27709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosp / Baylor Univ</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Puerto Rico / Univ Children's Hosp AIDS</name>
      <address>
        <city>San Juan</city>
        <zip>009365067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McKinney RE Jr. Ongoing and future trials of antiretroviral therapy in the pediatric AIDS clinical trials group (PACTG). Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:173</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ribavirin</keyword>
  <keyword>Didanosine</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

